Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: Report of two cases

Chang Gung Medical Journal

Volumn 25, Issue 9, 2002, Pages 606-611

  Lai, Wei Hao ^a   Lu, Shin Yu ^a   Eng, Hock Liew ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Levamisole; Myasthenia gravis; Oral candidiasis; Thymoma

Indexed keywords

AMPHOTERICIN B; LEVAMISOLE; NYSTATIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; CANDIDIASIS; CASE REPORT; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYASTHENIA GRAVIS; MYCOSIS; OPPORTUNISTIC INFECTION; STEM CELL; THRUSH; THYMOMA;

ADJUVANTS, IMMUNOLOGIC; ADULT; CANDIDIASIS, ORAL; CD4-CD8 RATIO; HUMANS; LEVAMISOLE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; THYMOMA; THYMUS NEOPLASMS;

EID: 0036760172     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Radentz WH. Opportunistic fungal infections in immunocompromised hosts. L Am Acad Dermatol 1989;20:989-1003.
2. Miller JFAP. Thymus and immunity, The last three decades. Eur J Cancer Clin Oncol 1988;24:1257-62.
3. Lampen JO. Amphotericin B and other polyene antifungal antibiotics. Am J Chem. Pathol 1969;52:138-46.
4. Lewinski U, Mavligib G, Hersh E. Cellular immune modulation after a single dose of levamisole in patients with carcinoma. Cancer 1980;46:2185-94.
5. Redondo JM, Lopez-Guerrero JA, Fresno M. Potentiation of interleukin-2 activity by levamisole and imidazole. Immunol Lett 1978;4:31-41.
6. Janssen PA. The levamisole story. Prog Drug Res 1976;20:347-83.
7. Lu SY, Chen WJ, Eng HL. Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus, a 6-year prospective follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:705-9.
8. Crompton GK. Efficacy of a new nystatin formulation in oral candidosis. Brit Med J 1986;293:270.
9. Hann IM, Corringham R, Keaney M. Ketaconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely compromised patients. Lancet 1982;1:826-9.
10. Hebeka EK, Solotorovsky M. Development of resistance to polyene antibiotics in Candida albicans. J of Bacteriology 1965;89:1533-9.
11. Fujii Y, Monden Y. Machi M. Antibody to acetylcholine receptor in myasthenia gravis: Production by lymphocytes from thymus or thymoma. Neurology 1984;34:1182-6.
12. Hankins JR, Mayer RF, Satterfield JR. Thymectomy for myasthenia gravis: 14 Years experience. Ann Surg 1985;201:613-5.
13. Levinson AI, Zweiman B, Lisak RP. Thymic B-cell activation in myasthenia gravis. Neurology 1984;34:462-8.
14. Melms A, Schalke BCG, Kirchner T. Thymus in myasthenia gravis: Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 1988;81:902-8.
15. Gregoire C. Thymus and immunity, Early thymus research. Eur J Cancer Clin Oncol 1988;24:1249-55.
16. Rogers T, Balish E, Manning DD. The role of thymus dependent cell-mediated immunity in resistance to experimental disseminated candidiasis. J Reticuloendothelial Society 1976;20:291-8.
17. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. New Eng J Med 1984;311:354-8.